8-K: Celularity Receives Nasdaq Deficiency Notice

Celularity Inc. has been notified by Nasdaq that its market value of listed securities has fallen below the required $35 million threshold.

Summary

• Celularity received a formal notice from Nasdaq on June 9, 2026, regarding non-compliance with the minimum Market Value of Listed Securities (MVLS) requirement.
• The company failed to maintain the $35 million minimum market value threshold for 30 consecutive business days.
• Nasdaq has granted a 180-day grace period, expiring on December 7, 2026, to regain compliance.
• To regain compliance, the company must maintain a market value of at least $35 million for at least 10 consecutive business days before the deadline.
• The company is currently evaluating options to regain compliance, including potentially increasing stockholders' equity to at least $2.5 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development that highlights significant downward pressure on the company's valuation and potential future listing risks.

Positives

• The company has been granted a clear 180-day window to rectify the deficiency before any delisting action occurs.
• The current listing on the Nasdaq Capital Market remains active and unaffected at this time.

Negatives

• The company is currently in violation of Nasdaq Listing Rule 5550(b)(2).
• The market value of the company's listed securities has remained below the $35 million threshold for at least 30 consecutive business days.
• There is no guarantee that the company will be able to regain compliance within the allotted timeframe.

Risks

• Potential delisting from the Nasdaq Capital Market if compliance is not regained by December 7, 2026.
• Negative impact on stock liquidity and investor sentiment due to the deficiency notice.
• Potential need for dilutive capital raises or other corporate actions to boost market value or equity.

Future Outlook

The company intends to monitor its market value and evaluate strategic options to regain compliance with Nasdaq listing standards before the December 7, 2026 deadline.

Management Comments

• The company is evaluating potential actions to regain compliance with the MVLS Requirement and intends to actively monitor the market value of its listed securities.

Industry Context

StockSavvy.ai notes that this notice is a common challenge for small-cap biotechnology firms facing market volatility, often necessitating strategic pivots or capital restructuring to maintain exchange eligibility.

Comparison to Industry Standards

• Nasdaq listing standards are standard for U.S. exchange-traded equities.
• Many small-cap biotech companies face similar 'compliance clock' scenarios during periods of clinical trial uncertainty or market downturns.

Stakeholder Impact

• Shareholders face uncertainty regarding the future listing status of the stock.
• Potential for increased volatility in the share price as the compliance deadline approaches.

Next Steps

• Monitor market value to ensure it stays above $35 million for 10 consecutive days.
• Evaluate strategic options to increase market value or stockholders' equity.
• Prepare for potential appeal if compliance is not met by December 7, 2026.

Key Dates

Recommendation

The receipt of a Nasdaq deficiency notice indicates significant financial distress and valuation concerns, which typically warrants a cautious or bearish stance until the company demonstrates a clear path to sustained compliance.

Keywords

Celularity, Nasdaq, Delisting, Compliance, Market Value, CELU, Biotech